{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036753","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-08-10T12:40:31+00:00","discovered_at":"2026-08-10T12:45:00.331061+00:00","generated_at":"2026-08-10T12:45:24.988503+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AIM ImmunoTech reports Q2 2026 net loss of $3.8M; completes Phase 2 pancreatic cancer enrollment","bullets":["Q2 2026 net loss of $3.8M ($0.43/share) vs $2.8M ($3.68/share) in Q2 2025; cash $9.9M vs $3.0M at year-end 2025.","Completed enrollment and Ampligen dosing in Phase 2 DURIPANC trial (metastatic pancreatic cancer) with AstraZeneca's Imfinzi.","Engaged Thermo Fisher's PPD for Phase 3 study design; anticipates DURIPANC clinical benefit data Q1 2027, OS data Q3 2027.","Ampligen showed median OS 34.8 months vs 12.5 months historical controls in Dutch Named Patient Program.","Regained full compliance with NYSE American listing standards; planning Ebola virus disease initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036753","json":"https://secwatch.observer/filing/0001493152-26-036753.json","markdown":"https://secwatch.observer/filing/0001493152-26-036753.md","text":"https://secwatch.observer/filing/0001493152-26-036753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/0001493152-26-036753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T12:45:24.988503+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}